Published in Nature on April 21, 2004
Modes of p53 regulation. Cell (2009) 9.31
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer (2006) 8.83
Acetylation is indispensable for p53 activation. Cell (2008) 5.70
p53 ubiquitination: Mdm2 and beyond. Mol Cell (2006) 5.57
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell (2007) 3.20
The ConsensusPathDB interaction database: 2013 update. Nucleic Acids Res (2012) 2.94
The ubiquitin-proteasome pathway and plant development. Plant Cell (2004) 2.72
Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol (2005) 2.72
CONSTITUTIVELY PHOTOMORPHOGENIC1 is required for the UV-B response in Arabidopsis. Plant Cell (2006) 2.57
ROS and p53: a versatile partnership. Free Radic Biol Med (2008) 2.52
Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A (2007) 2.36
HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53. Genes Dev (2007) 2.32
Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J (2006) 2.12
Negative regulation of NF-kappaB action by Set9-mediated lysine methylation of the RelA subunit. EMBO J (2009) 2.05
Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol (2006) 2.02
The multiple levels of regulation by p53 ubiquitination. Cell Death Differ (2010) 1.87
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A (2006) 1.82
Ubiquitination and degradation of mutant p53. Mol Cell Biol (2007) 1.77
Stealing the spotlight: CUL4-DDB1 ubiquitin ligase docks WD40-repeat proteins to destroy. Cell Div (2007) 1.70
The impact of acetylation and deacetylation on the p53 pathway. Protein Cell (2011) 1.66
Arabidopsis CULLIN4-damaged DNA binding protein 1 interacts with CONSTITUTIVELY PHOTOMORPHOGENIC1-SUPPRESSOR OF PHYA complexes to regulate photomorphogenesis and flowering time. Plant Cell (2010) 1.66
The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage. Cell Res (2012) 1.66
The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol (2010) 1.64
The phenotype of MDM2 auto-degradation after DNA damage is due to epitope masking by phosphorylation. Cell Cycle (2011) 1.62
Fast alkene functionalization in vivo by Photoclick chemistry: HOMO lifting of nitrile imine dipoles. Angew Chem Int Ed Engl (2009) 1.62
Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. J Clin Invest (2011) 1.59
BRCA1/BARD1 inhibition of mRNA 3' processing involves targeted degradation of RNA polymerase II. Genes Dev (2005) 1.57
p53 Stabilization and accumulation induced by human vaccinia-related kinase 1. Mol Cell Biol (2004) 1.56
CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc Natl Acad Sci U S A (2009) 1.53
TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest (2009) 1.50
E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia (2006) 1.49
Inactivation of HAUSP in vivo modulates p53 function. Oncogene (2009) 1.48
Transcriptional regulation of HIV-1 gene expression by p53. Cell Cycle (2010) 1.47
Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J (2004) 1.47
Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J (2006) 1.45
Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc Natl Acad Sci U S A (2009) 1.45
Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J (2009) 1.45
The chaperone-assisted E3 ligase C terminus of Hsc70-interacting protein (CHIP) targets PTEN for proteasomal degradation. J Biol Chem (2012) 1.44
The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. Proc Natl Acad Sci U S A (2005) 1.44
Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol (2009) 1.41
Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1. EMBO J (2011) 1.38
Roles of COP9 signalosome in cancer. Cell Cycle (2011) 1.37
DNA polymerase eta, the product of the xeroderma pigmentosum variant gene and a target of p53, modulates the DNA damage checkpoint and p53 activation. Mol Cell Biol (2006) 1.35
Endoplasmic reticulum stress accelerates p53 degradation by the cooperative actions of Hdm2 and glycogen synthase kinase 3beta. Mol Cell Biol (2005) 1.35
Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc. Neoplasia (2006) 1.34
Molecular basis of Pirh2-mediated p53 ubiquitylation. Nat Struct Mol Biol (2008) 1.32
COP9 signalosome subunit 6 stabilizes COP1, which functions as an E3 ubiquitin ligase for 14-3-3σ. Oncogene (2011) 1.31
Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Oncogene (2006) 1.29
E3 ubiquitin ligase COP1 regulates the stability and functions of MTA1. Proc Natl Acad Sci U S A (2009) 1.28
Multiple stress signals activate mutant p53 in vivo. Cancer Res (2011) 1.27
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood (2010) 1.27
Regulation of p53 localization and activity by Ubc13. Mol Cell Biol (2006) 1.26
USP4 inhibits p53 through deubiquitinating and stabilizing ARF-BP1. EMBO J (2011) 1.26
Targeting p53 for Novel Anticancer Therapy. Transl Oncol (2010) 1.26
FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity. J Biol Chem (2006) 1.26
p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop. Mol Cell Biol (2006) 1.26
Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Mol Cell Biol (2005) 1.25
Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2. Proc Natl Acad Sci U S A (2008) 1.22
Autoubiquitination of BCA2 RING E3 ligase regulates its own stability and affects cell migration. Mol Cancer Res (2008) 1.21
COP1 functions as a FoxO1 ubiquitin E3 ligase to regulate FoxO1-mediated gene expression. J Biol Chem (2008) 1.16
Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding. Blood (2010) 1.16
Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators. Mol Cell Biol (2005) 1.15
A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther (2010) 1.13
Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci U S A (2005) 1.13
PACT is a negative regulator of p53 and essential for cell growth and embryonic development. Proc Natl Acad Sci U S A (2007) 1.12
UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat Med (2011) 1.12
Versatile functions of p53 protein in multicellular organisms. Biochemistry (Mosc) (2007) 1.11
14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability. Cancer Res (2010) 1.11
Autoregulatory control of the p53 response by caspase-mediated processing of HIPK2. EMBO J (2006) 1.10
Functional interconnection of MYC2 and SPA1 in the photomorphogenic seedling development of Arabidopsis. Plant Physiol (2010) 1.09
Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle (2010) 1.09
Targeted inactivation of the COP9 signalosome impairs multiple stages of T cell development. J Exp Med (2008) 1.08
Pathogenic Role of the CRL4 Ubiquitin Ligase in Human Disease. Front Oncol (2012) 1.08
E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. Cell Death Differ (2014) 1.07
Spotlight on the role of COP1 in tumorigenesis. Nat Rev Cancer (2012) 1.06
Induction of cullin 7 by DNA damage attenuates p53 function. Proc Natl Acad Sci U S A (2007) 1.06
New insights into p53 activation. Cell Res (2010) 1.06
Nuclear export regulation of COP1 by 14-3-3σ in response to DNA damage. Mol Cancer (2010) 1.06
Uncovering ubiquitin and ubiquitin-like signaling networks. Chem Rev (2011) 1.06
TRAF7 protein promotes Lys-29-linked polyubiquitination of IkappaB kinase (IKKgamma)/NF-kappaB essential modulator (NEMO) and p65/RelA protein and represses NF-kappaB activation. J Biol Chem (2011) 1.05
Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. Cancer Res (2010) 1.05
Regulation of p53 and MDM2 activity by MTBP. Mol Cell Biol (2005) 1.05
Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia (2006) 1.05
MTA1 coregulator regulates p53 stability and function. J Biol Chem (2009) 1.04
Myeloid leukemia factor 1 regulates p53 by suppressing COP1 via COP9 signalosome subunit 3. EMBO J (2005) 1.04
E6-associated protein (E6-AP) is a dual function coactivator of steroid hormone receptors. Nucl Recept Signal (2008) 1.04
CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome. EMBO J (2007) 1.04
BLIMP1 regulates cell growth through repression of p53 transcription. Proc Natl Acad Sci U S A (2007) 1.03
Isg15 controls p53 stability and functions. Cell Cycle (2014) 1.02
JMJD6 promotes colon carcinogenesis through negative regulation of p53 by hydroxylation. PLoS Biol (2014) 1.01
CSN6 deregulation impairs genome integrity in a COP1-dependent pathway. Oncotarget (2015) 1.01
Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2. J Biol Chem (2010) 1.00
Inactivation of arf-bp1 induces p53 activation and diabetic phenotypes in mice. J Biol Chem (2011) 1.00
Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin. Cancer Res (2009) 1.00
TRIM24 is a p53-induced E3-ubiquitin ligase that undergoes ATM-mediated phosphorylation and autodegradation during DNA damage. Mol Cell Biol (2014) 1.00
JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 regulation. Proc Natl Acad Sci U S A (2009) 1.00
Regulation of MDM2 E3 ligase activity by phosphorylation after DNA damage. Mol Cell Biol (2011) 1.00
Inhibition of TFII-I-dependent cell cycle regulation by p53. Mol Cell Biol (2005) 1.00
A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. Neoplasia (2011) 1.00
Cryopyrin activates the inflammasome in response to toxins and ATP. Nature (2006) 18.74
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature (2004) 14.80
De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature (2004) 12.41
Non-canonical inflammasome activation targets caspase-11. Nature (2011) 8.85
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell (2007) 8.48
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell (2008) 5.37
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32
Recurrent R-spondin fusions in colon cancer. Nature (2012) 5.10
Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science (2013) 5.06
Innate immunity against Francisella tularensis is dependent on the ASC/caspase-1 axis. J Exp Med (2005) 5.00
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of Legionella pneumophila infection. Nat Immunol (2006) 4.70
Absent in melanoma 2 is required for innate immune recognition of Francisella tularensis. Proc Natl Acad Sci U S A (2010) 4.57
Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella. J Exp Med (2010) 4.52
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature (2009) 4.12
Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol Cell Biol (2004) 4.05
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol (2005) 4.02
Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature (2003) 3.96
DUBA: a deubiquitinase that regulates type I interferon production. Science (2007) 3.88
Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol (2009) 3.85
Inflammasomes: guardians of cytosolic sanctity. Immunol Rev (2009) 3.58
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
Caspase-11 increases susceptibility to Salmonella infection in the absence of caspase-1. Nature (2012) 3.40
Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science (2003) 3.28
Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science (2004) 3.28
A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci U S A (2008) 3.27
Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol (2012) 3.18
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol (2010) 3.15
The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. Cell (2007) 3.13
Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol (2012) 3.11
Automated de novo protein sequencing of monoclonal antibodies. Nat Biotechnol (2008) 3.02
The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res (2003) 2.91
Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol (2010) 2.88
BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity (2002) 2.75
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst (2005) 2.74
Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (2012) 2.69
Pannexin-1 is required for ATP release during apoptosis but not for inflammasome activation. J Immunol (2011) 2.67
K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody. Mol Cell (2010) 2.52
USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell (2011) 2.51
Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity (2003) 2.51
Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. J Biol Chem (2001) 2.45
Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol (2009) 2.36
Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J Exp Med (2011) 2.35
Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer (2006) 2.27
Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol (2011) 2.27
Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol Cell Biol (2009) 2.26
Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science (2014) 2.23
Manipulation of host cell death pathways during microbial infections. Cell Host Microbe (2010) 2.21
Signaling to NF-kappaB: regulation by ubiquitination. Cold Spring Harb Perspect Biol (2010) 2.15
Mice lacking the CARD of CARMA1 exhibit defective B lymphocyte development and impaired proliferation of their B and T lymphocytes. Curr Biol (2003) 2.04
A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol (2002) 2.02
Autophosphorylated CaMKIIalpha acts as a scaffold to recruit proteasomes to dendritic spines. Cell (2010) 2.02
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
Deubiquitinases in the regulation of NF-κB signaling. Cell Res (2010) 2.00
Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1). Biochem J (2009) 1.94
Engineering and structural characterization of a linear polyubiquitin-specific antibody. J Mol Biol (2011) 1.93
Deubiquitinase USP37 is activated by CDK2 to antagonize APC(CDH1) and promote S phase entry. Mol Cell (2011) 1.92
Phosphorylation of NLRC4 is critical for inflammasome activation. Nature (2012) 1.92
The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res (2007) 1.90
Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-kappa B activation. J Exp Med (2005) 1.85
Modulation of inflammasome pathways by bacterial and viral pathogens. J Immunol (2011) 1.85
COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature (2011) 1.83
Regulation of NF-κB by deubiquitinases. Immunol Rev (2012) 1.78
Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell (2005) 1.74
Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity (2009) 1.73
Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res (2005) 1.69
Identification and immunotherapeutic targeting of antigens induced by chemotherapy. Nat Biotechnol (2006) 1.68
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J Natl Cancer Inst (2013) 1.68
ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage. Science (2006) 1.64
DNA-dependent acetylation of p53 by the transcription coactivator p300. J Biol Chem (2002) 1.59
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res (2011) 1.56
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res (2012) 1.55
WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. Am J Pathol (2004) 1.53
HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res (2004) 1.49
The inflammasomes. PLoS Pathog (2009) 1.48
Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival. PLoS One (2007) 1.44
p21-activated kinase 1: PAK'ed with potential. Oncotarget (2011) 1.44
Improved quantitative mass spectrometry methods for characterizing complex ubiquitin signals. Mol Cell Proteomics (2010) 1.43
Phosphorylation-dependent activity of the deubiquitinase DUBA. Nat Struct Mol Biol (2012) 1.42